Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 9534726

Radionuclide developments.

C M Medley·G C Vivian
View original source ↗Export metadata ↓

Abstract

This review considers a number of recent important developments in nuclear medicine, and possible future introductions, priority being given to those products which are most likely to find a place in clinical practice. This includes both novel radiopharmaceuticals and progress with new types of imaging equipment. Three areas are chosen as being of particular importance: brain imaging, heart imaging, and diagnosis and therapy of cancer. In the brain, the clinical value of imaging regional cerebral blood flow and certain aspects of the neuroreceptor/neurotransmitter system are discussed. Cardiac imaging is considered in the light of recent work on diagnosis and risk assessment, investigating the hibernating myocardium, and the possible place of fatty acid imaging. Both diagnosis and therapy of cancer are increasingly important, and the use of radionuclides in these areas in considered.

Explore related subjects

Bone NeoplasmsBrainCerebrovascular DisordersHeartHumansRadioimmunotherapyRadionuclide ImagingRadiotherapyThrombosisJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C M Medley, G C Vivian. 1997. Radionuclide developments.. https://doi.org/10.1259/bjr.1997.0016

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.

BACKGROUND: Unlike most other malignancies, prostate cancer metastasizes preferentially to the skeleton and elicits osteoblastic reactions. METHODS: We present a hypothesis, based upon results obtained from our laboratory and others, on the nature of progression of prostate cancer cells and their predilection to growth and metastasis in the bone microenvironment. We propose the hypothesis that osseous metastatic prostate cancer cells must be osteomimetic in order to metastasize, grow, and survive in the skeleton. The reciprocal interaction between prostate cancer and bone stromal growth factors, including basic fibroblast growth factor (bFGF), hepatocyte growth factor/scatter factor (HGF/SF), and especially the insulin growth factor (IGF) axis initiates bone tropism, and is enhanced by prostate secreted endothelin-1 (ET-1) and urokinase-type plasminogen activator (uPA). Growth factors and peptides that have differentiating activity, such as transforming growth factor beta (TGF-beta), parathyroid hormone-related protein (PTH-rp), and the bone morphogenetic proteins (BMPs), can shift local homeostasis to produce the characteristic blastic phenotype, via interaction with prostate-secreted human kalikrein 2 (hK2), and prostate-specific antigen (PSA). This proposal asserts that altering the expression of certain critical transcription factors, such as Cbfa and MSX in prostate cancer cells, which presumably are under the inductive influences of prostate or bone stromal cells, can confer profiles of gene expression, such as osteopontin (OPN), osteocalcin (OC), and bone sialoprotein (BSP), that mimic that of osteoblasts. RESULTS AND CONCLUSIONS: Elucidation of common proteins, presumably driven by the same promoters, expressed by both prostate cancer and bone stromal cells, could result in the development of novel preventive and therapeutic strategies for the treatment of prostate cancer skeletal metastasis. Agents developed using these strategies could have the potential advantage of interfering with growth and enhancing apoptosis in both prostate cancer and bone stromal compartments. The selective application of gene therapy strategy, driven by tissue-specific and tumor-restricted promoters for the safe delivery and expression of therapeutic genes in experimental models of prostate cancer metastasis, is discussed.

Bone Neoplasms↗